News & Updates
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population…
Read More
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Excerpt from the Press Release: BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE)…
Read More
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) —…
Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ART5803. ART5803 is a therapeutic monoclonal antibody candidate designed to specifically compete with pathogenic autoantibodies targeting the NMDA…
Read More
New lab and scientific talent in Toronto to strengthen cell therapy developmentcapabilities in Canada Excerpt from the Press Release: TORONTO and SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ — cTRL Therapeutics, a biotechnology company advancing next-generation cell therapies for solid tumors, announced that it has secured a follow-on investment from FACIT, further enabling cTRL to build out…
Read More
The Merlin Test (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, Oct. 11, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory,…
Read More
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected…
Read More
The National Institute of Diabetes and Digestive and Kidney Diseases Awards Vaxess SBIR Phase I Funding to Test Company’s MIMIX Transdermal Patch Platform in Administering GLP-1 RA Therapies Excerpt from the Press Release: CAMBRIDGE, Mass., October 1, 2024 — Vaxess Technologies, Inc., a biotech company developing a novel transdermal patch technology to transform home delivery…
Read More
Findings are from the prospective, multicenter VANDAAM trial Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease.…
Read More
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc.…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?